Table 2 |
|
|
Advantages and disadvantages of dabigatran over VKA |
|
|
Advantages over VKA |
Disadvantages over VKA |
|
|
|
|
No need of periodic INR control |
High prize |
|
|
|
|
Lower interactions |
Not indicated in renal disease |
|
|
|
|
Favorable safety versus efficacy profile, it may reduce VKA misdosing |
No antidote and lack of experience in hemorrhage complications |
|
|
|
|
Redondo et al. Journal of Hematology & Oncology 2011 4:53 doi:10.1186/1756-8722-4-53 |
|